Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates that blocking myostatin and activin A prevents muscle and bone loss in spaceflight mice, highlighting potential therapies for disuse atrophy.
mice, were largely maintained during spaceflight. Systemic inhibition of MSTN/activin A signaling using a soluble form of the activin type IIB receptor (ACVR2B), which can bind each of these ligands, led to dramatic increases in both muscle and bone mass, with effects being comparable in ground and flight mice. Exposure to microgravity and treatment with the soluble receptor each led to alterations in numerous signaling pathways, which were reflected in changes in levels of key signaling components in the blood as well as their RNA expression levels in muscle and bone. These findings have implications for therapeutic strategies to combat the concomitant muscle and bone loss occurring in people afflicted with disuse atrophy on Earth as well as in astronauts in space, especially during prolonged missions.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: